Endospan is enrolling patients for the TRIOMPHE IDE Study. Credit: New Africa / Shutterstock.

Endospan, the developer of the Nexus Stent Graft System, has announced a funding agreement with medical device company Artivion for up to $25m of additional loans.

The funds are earmarked for the pursuit of the US Food and Drug Administration (FDA) approval for Nexus, an endovascular off-the-shelf system designed to treat aortic arch disease, including both aortic aneurysms and aortic dissection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Said to be the first and only approved branched endovascular system for aortic arch disease treatment, Nexus offers an alternative to open-chest surgery, which is known for its invasiveness and associated risks.

It aims to address the specific challenges related to the aortic arch anatomy.

Endospan is currently enrolling patients for the TRIOMPHE IDE Study, which will involve up to 110 patients across up to 31 sites.

TRIOMPHE is a multi-arm, multi-centre, non-randomised, prospective, clinical study. It aims to assess Nexus’ safety and effectiveness in treating thoracic aortic lesions involving the aortic arch.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Endospan said that the 30-day results of the first 22 patients enrolled for the study have been consistent with previous EU clinical studies. This indicated that the Nexus system could offer a reliable and minimally invasive solution for aortic arch repair.

Endospan CEO Kevin Mayberry said: “We’re excited to progress in our IDE study with the FDA and extending options for more patients with aortic arch disease through this agreement with Artivion.

“We share a commitment with Artivion to delivering minimally invasive solutions to help surgeons address the complex challenges of this growing market.”